Loading…
A Proposed Methodology for a Risk Assessment-Based Liposome Development Process
The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and pr...
Saved in:
Published in: | Pharmaceutics 2020-11, Vol.12 (12), p.1164 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3 |
container_end_page | |
container_issue | 12 |
container_start_page | 1164 |
container_title | Pharmaceutics |
container_volume | 12 |
creator | Németh, Zsófia Pallagi, Edina Dobó, Dorina Gabriella Csóka, Ildikó |
description | The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and process parameters (PPs) (settings of the preparation method). The identification of the quality target product profile for a liposome-based formulation, the critical quality attributes of the liposomes, and the possible MAs and PPs that may influence the key characteristics of the vesicles facilitates pharmaceutical research. Researchers can systematise their knowledge by using the quality by design (QbD) approach. The potential factors that influence the quality of the product can be collected and studied through a risk assessment process. In this paper, the requirements of a liposome formulation prepared via the thin-film hydration preparation technique are presented; furthermore, the possible factors that have an impact on the quality of the final product and have to be considered and specified during the development of a liposomal formulation are herein identified and collected. The understanding and the application of these elements of QbD in the pharmaceutical developments help to influence the quality, the achievements, and the success of the formulated product. |
doi_str_mv | 10.3390/pharmaceutics12121164 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7f1d87539f2646de9cb0f6e7f79ca7e7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7f1d87539f2646de9cb0f6e7f79ca7e7</doaj_id><sourcerecordid>2467238502</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3</originalsourceid><addsrcrecordid>eNptkk1P3DAQhi3UqiDKTyiK1Esvaf3t-FJp-WqRFoFQe7YcZ7ybbbJO7QSJf4_DUgSo9sEjzzOv_I4HoU8Ef2VM42_D2sbeOpjG1iVC8yaS76EDorUuuabs3Yt4Hx2ltMF5MUYqpj-gfcaoxJyzA3S9KG5iGEKCpriCcR2a0IXVfeFDLGxx26Y_xSIlSKmH7Vie2JlbtpkPPRRncAddGObUrOIy9hG997ZLcPR0HqLfF-e_Tn-Wy-sfl6eLZekEFmMpGLOEaC69rLgSjaot195VUtcgndOEskroJhvztXAgFYbsklLJMHeicuwQXe50m2A3Zohtb-O9CbY1jxchroyNuTsdGOVJUynBtKeSywa0q7GXoLzSzipQWev7TmuY6h4al-1E270SfZ3ZtmuzCndGKYkrxbPAlyeBGP5OkEbTt8lB19kthCkZyqWkmjM6o5_foJswxW1u1Uyp2TammRI7ysWQUgT__BiCzTwB5r8TkOuOXzp5rvr33-wBJlmvrg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2467238502</pqid></control><display><type>article</type><title>A Proposed Methodology for a Risk Assessment-Based Liposome Development Process</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Németh, Zsófia ; Pallagi, Edina ; Dobó, Dorina Gabriella ; Csóka, Ildikó</creator><creatorcontrib>Németh, Zsófia ; Pallagi, Edina ; Dobó, Dorina Gabriella ; Csóka, Ildikó</creatorcontrib><description>The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and process parameters (PPs) (settings of the preparation method). The identification of the quality target product profile for a liposome-based formulation, the critical quality attributes of the liposomes, and the possible MAs and PPs that may influence the key characteristics of the vesicles facilitates pharmaceutical research. Researchers can systematise their knowledge by using the quality by design (QbD) approach. The potential factors that influence the quality of the product can be collected and studied through a risk assessment process. In this paper, the requirements of a liposome formulation prepared via the thin-film hydration preparation technique are presented; furthermore, the possible factors that have an impact on the quality of the final product and have to be considered and specified during the development of a liposomal formulation are herein identified and collected. The understanding and the application of these elements of QbD in the pharmaceutical developments help to influence the quality, the achievements, and the success of the formulated product.</description><identifier>ISSN: 1999-4923</identifier><identifier>EISSN: 1999-4923</identifier><identifier>DOI: 10.3390/pharmaceutics12121164</identifier><identifier>PMID: 33260443</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>critical factors ; Design of experiments ; Drug dosages ; Generations ; liposome formulation ; Nanoparticles ; Pharmaceutical industry ; Polyethylene glycol ; quality by design ; quality planning ; Risk assessment ; Software ; thin-film hydration method</subject><ispartof>Pharmaceutics, 2020-11, Vol.12 (12), p.1164</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3</citedby><cites>FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3</cites><orcidid>0000-0003-3953-9831</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2467238502/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2467238502?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,36994,44571,53772,53774,74875</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33260443$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Németh, Zsófia</creatorcontrib><creatorcontrib>Pallagi, Edina</creatorcontrib><creatorcontrib>Dobó, Dorina Gabriella</creatorcontrib><creatorcontrib>Csóka, Ildikó</creatorcontrib><title>A Proposed Methodology for a Risk Assessment-Based Liposome Development Process</title><title>Pharmaceutics</title><addtitle>Pharmaceutics</addtitle><description>The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and process parameters (PPs) (settings of the preparation method). The identification of the quality target product profile for a liposome-based formulation, the critical quality attributes of the liposomes, and the possible MAs and PPs that may influence the key characteristics of the vesicles facilitates pharmaceutical research. Researchers can systematise their knowledge by using the quality by design (QbD) approach. The potential factors that influence the quality of the product can be collected and studied through a risk assessment process. In this paper, the requirements of a liposome formulation prepared via the thin-film hydration preparation technique are presented; furthermore, the possible factors that have an impact on the quality of the final product and have to be considered and specified during the development of a liposomal formulation are herein identified and collected. The understanding and the application of these elements of QbD in the pharmaceutical developments help to influence the quality, the achievements, and the success of the formulated product.</description><subject>critical factors</subject><subject>Design of experiments</subject><subject>Drug dosages</subject><subject>Generations</subject><subject>liposome formulation</subject><subject>Nanoparticles</subject><subject>Pharmaceutical industry</subject><subject>Polyethylene glycol</subject><subject>quality by design</subject><subject>quality planning</subject><subject>Risk assessment</subject><subject>Software</subject><subject>thin-film hydration method</subject><issn>1999-4923</issn><issn>1999-4923</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1P3DAQhi3UqiDKTyiK1Esvaf3t-FJp-WqRFoFQe7YcZ7ybbbJO7QSJf4_DUgSo9sEjzzOv_I4HoU8Ef2VM42_D2sbeOpjG1iVC8yaS76EDorUuuabs3Yt4Hx2ltMF5MUYqpj-gfcaoxJyzA3S9KG5iGEKCpriCcR2a0IXVfeFDLGxx26Y_xSIlSKmH7Vie2JlbtpkPPRRncAddGObUrOIy9hG997ZLcPR0HqLfF-e_Tn-Wy-sfl6eLZekEFmMpGLOEaC69rLgSjaot195VUtcgndOEskroJhvztXAgFYbsklLJMHeicuwQXe50m2A3Zohtb-O9CbY1jxchroyNuTsdGOVJUynBtKeSywa0q7GXoLzSzipQWev7TmuY6h4al-1E270SfZ3ZtmuzCndGKYkrxbPAlyeBGP5OkEbTt8lB19kthCkZyqWkmjM6o5_foJswxW1u1Uyp2TammRI7ysWQUgT__BiCzTwB5r8TkOuOXzp5rvr33-wBJlmvrg</recordid><startdate>20201129</startdate><enddate>20201129</enddate><creator>Németh, Zsófia</creator><creator>Pallagi, Edina</creator><creator>Dobó, Dorina Gabriella</creator><creator>Csóka, Ildikó</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3953-9831</orcidid></search><sort><creationdate>20201129</creationdate><title>A Proposed Methodology for a Risk Assessment-Based Liposome Development Process</title><author>Németh, Zsófia ; Pallagi, Edina ; Dobó, Dorina Gabriella ; Csóka, Ildikó</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>critical factors</topic><topic>Design of experiments</topic><topic>Drug dosages</topic><topic>Generations</topic><topic>liposome formulation</topic><topic>Nanoparticles</topic><topic>Pharmaceutical industry</topic><topic>Polyethylene glycol</topic><topic>quality by design</topic><topic>quality planning</topic><topic>Risk assessment</topic><topic>Software</topic><topic>thin-film hydration method</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Németh, Zsófia</creatorcontrib><creatorcontrib>Pallagi, Edina</creatorcontrib><creatorcontrib>Dobó, Dorina Gabriella</creatorcontrib><creatorcontrib>Csóka, Ildikó</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Németh, Zsófia</au><au>Pallagi, Edina</au><au>Dobó, Dorina Gabriella</au><au>Csóka, Ildikó</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Proposed Methodology for a Risk Assessment-Based Liposome Development Process</atitle><jtitle>Pharmaceutics</jtitle><addtitle>Pharmaceutics</addtitle><date>2020-11-29</date><risdate>2020</risdate><volume>12</volume><issue>12</issue><spage>1164</spage><pages>1164-</pages><issn>1999-4923</issn><eissn>1999-4923</eissn><abstract>The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and process parameters (PPs) (settings of the preparation method). The identification of the quality target product profile for a liposome-based formulation, the critical quality attributes of the liposomes, and the possible MAs and PPs that may influence the key characteristics of the vesicles facilitates pharmaceutical research. Researchers can systematise their knowledge by using the quality by design (QbD) approach. The potential factors that influence the quality of the product can be collected and studied through a risk assessment process. In this paper, the requirements of a liposome formulation prepared via the thin-film hydration preparation technique are presented; furthermore, the possible factors that have an impact on the quality of the final product and have to be considered and specified during the development of a liposomal formulation are herein identified and collected. The understanding and the application of these elements of QbD in the pharmaceutical developments help to influence the quality, the achievements, and the success of the formulated product.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33260443</pmid><doi>10.3390/pharmaceutics12121164</doi><orcidid>https://orcid.org/0000-0003-3953-9831</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1999-4923 |
ispartof | Pharmaceutics, 2020-11, Vol.12 (12), p.1164 |
issn | 1999-4923 1999-4923 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_7f1d87539f2646de9cb0f6e7f79ca7e7 |
source | Publicly Available Content Database; PubMed Central |
subjects | critical factors Design of experiments Drug dosages Generations liposome formulation Nanoparticles Pharmaceutical industry Polyethylene glycol quality by design quality planning Risk assessment Software thin-film hydration method |
title | A Proposed Methodology for a Risk Assessment-Based Liposome Development Process |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T16%3A36%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Proposed%20Methodology%20for%20a%20Risk%20Assessment-Based%20Liposome%20Development%20Process&rft.jtitle=Pharmaceutics&rft.au=N%C3%A9meth,%20Zs%C3%B3fia&rft.date=2020-11-29&rft.volume=12&rft.issue=12&rft.spage=1164&rft.pages=1164-&rft.issn=1999-4923&rft.eissn=1999-4923&rft_id=info:doi/10.3390/pharmaceutics12121164&rft_dat=%3Cproquest_doaj_%3E2467238502%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2467238502&rft_id=info:pmid/33260443&rfr_iscdi=true |